• BIOMONITOR IV
  • BIOMONITOR IV

    BIOMONITOR IV

    Intelligence. Confidence. Clarity

    A real challenge exists in the clinical world today with the volume of data generated as more patients benefit from the proven value of long-term cardiac monitoring. Valuable time and resources are spent analyzing false positive arrhythmias, leaving patients waiting for accurate answers. The intelligent technology in BIOMONITOR IV can help.



    BIOMONITOR IV with SmartECG leverages artificial intelligence (AI) and advanced detection algorithms to reduce 86% of false positives across all major arrhythmias,1 alleviating the review burden and helping clinicians achieve timely and accurate diagnosis to focus on what’s most important – the patient.

     

    Category

    Implantable Cardiac Monitor

    Product Highlights

    Intelligent SmartECG

    Intelligent SmartECG

    AI and advanced detection algorithms reduce 86% of false positives across all major arrhythmias1 to alleviate the review burden

    Confidence from BIOTRONIK Home Monitoring

    Confidence from BIOTRONIK Home Monitoring

    Streamlined ICM monitoring with indication-specific templates, enhanced automaticity, and intuitive reports

    Clarity with PVC/PAC Diagnostics

    Clarity with PVC/PAC Diagnostics

    The industry’s first to discriminate between PVCs and PACs and clearly report burden over time for personalized treatment decisions

    Intelligent SmartECG

    Intelligent SmartECG

    BIOMONITOR IV comes with SmartECG, an intelligent system powered by AI and advanced algorithms to reduce the number of false positive detections for Atrial Fibrillation (AF), Bradycardia, Tachycardia, and Pause.1,2 This allows you to focus on actionable events and spend more time on patient care.

    • SmartECG reduces 86% of false detections across all major arrhythmias while keeping 98% of the clinically relevant episodes.3
    • A recent publication by Bisignani et al. shows a meaningful workload reduction by SmartECG and up to 42% reduced time spent for episode reviews.4
    • False positive AF detections may take a considerable amount of time to review. That’s why SmartECG is supported by AI for AF detection to analyze 100s of data points across each individual ECG and streamline data evaluation.

     

     

    86% Reduction of All False Positive Detections3

    86% reduced false positive detection with smart ECG

    Confidence from BIOTRONIK Home Monitoring

    Confidence from BIOTRONIK Home Monitoring

    When it comes to system set-up, BIOMONITOR IV offers indication-specific templates, enhanced automaticity and intuitive reports for efficient access to optimized clinical data and insights. BIOTRONIK Home Monitoring® delivers on the promise of improving patient outcomes and driving operational efficiency.

    • Industry-leading 98% daily transmission reliability5
    • Earlier access to symptomatic episodes with On-demand transmission
    • Enhanced Quick View report for easy and efficient review

     

     

    New Condensed Quick View Report

    Confidence from BIOTRONIK Home Monitoring

    Clarity with PVC/PAC Discrimination

    Clarity with PVC/PAC Discrimination

    BIOTRONIK’s BIOMONITOR IV is the industry’s first to discriminate between premature ventricular and atrial contractions (PVCs and PACs) and clearly report burden over time.6,7 BIOMONITOR IV brings a new level of intelligence to achieve accurate risk stratification based on the PVC and PAC burden and the related therapy strategy.

    • High frequency of PVCs and PACs is associated with the development of AF, and with an increased risk of stroke, heart failure, and death8,9,10
    • High PVC burden increases the risk of the combined endpoint of all-cause mortality, cardiovascular mortality, sudden cardiac death, or development of ischemic heart disease10
    • High PVC burden is associated with 3-fold greater odds for left ventricular ejection fraction decline (after 5 years), a 48% increased risk of congestive heart failure incident (after 13 years), and a 31% increased risk of death (after 15 years)11

       

     

    Long-term Diagnostic Trends Including PVC and PAC Ectopic Burden

    PVC

    Product Overview

    BIOMONITOR IV

    Media

    BIOMONITOR IV Insertable Cardiac Monitor – Intelligence. Confidence. Clarity.
    BIOMONITOR IV One-Step Injection
    SmartECG Explained: How SmartECG Can Help Improve Arrhythmia Detection

    Downloads & Related Links

    Manual Library ProMRI SystemCheck ProMRI Configurator

    Related Products

      Contact Us

      I prefer to be contacted by
      *Fields are mandatory.

      References

      1. Kapur et al., AI/machine learning AF algorithm improves clinical workflow in ICM. Presented at 16th Asia Pacific Heart Rhythm Society Scientific Session in Conjunction with CardioRhythm (APHRS 2023), 31 August - 3 September, Hong Kong; 2. Iwai et al., Novel automated overread strategy significantly improves clinical workflow in ICM remote monitoring. Presented at 16th Asia Pacific Heart Rhythm Society Scientific Session in Conjunction with CardioRhythm (APHRS 2023), 31 August - 3 September, Hong Kong; 3. SmartECG AF filtering programmed to Very Specific. Sensitivity and specificity depend on the programmed SmartECG filter configuration. Data on file 2023; 4. Bisignani et al., Implantable cardiac monitors: Artificial intelligence and signal processing reduce remote ECG review workload and preserve arrhythmia detection sensitivity. Frontiers in Cardiovascular Medicine. Volume 11 - 2024. doi: 10.3389/fcvm.2024.1343424; 5. Mariani JA, Weerasooriya R, van den Brink O, Mohamed U, Gould PA, Pathak RK, et al. Miniaturized implantable cardiac monitor with a long sensing vector (BIOMONITOR III): Insertion procedure assessment, sensing performance, and home monitoring transmission success. J Electrocardiol. 2020;60:118–25. doi: 10.1016/j.jelectrocard.2020.04.004; 6. Dukes et al., Novel PVC detection algorithm in an implantable cardiac monitor for longitudinal risk monitoring. Presented at ESC Congress 2023, August 25-27; Amsterdam, Netherlands; 7. Marmerstein, Joseph, et al. Evaluation of a Novel PVC and PAC Detection Algorithm in an Implantable Cardiac Monitor for Longitudinal Risk Monitoring. Hearty Rhythm O2, Aug. 2023; 8. Binici Z, Intzilakis T, Nielsen OW, Køber L, Sajadieh A. Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke. Circulation. 2010;121(17):1904–11. doi: 10.1161/CIRCULATIONAHA.109.874982; 9. Larsen BS, Kumarathurai P, Falkenberg J, Nielsen OW, Sajadieh A. Excessive Atrial Ectopy and Short Atrial Runs Increase the Risk of Stroke Beyond Incident Atrial Fibrillation. J Am Coll Cardiol. 2015;66(3):232–41. doi: 10.1016/j.jacc.2015.05.018; 10. Todo K, Iwata T, Doijiri R, Yamagami H, Morimoto M, Hashimoto T, et al. Frequent Premature Atrial Contractions in Cryptogenic Stroke Predict Atrial Fibrillation Detection with Insertable Cardiac Monitoring. Cerebrovasc Dis. 2020:1–7. doi: 10.1159/000505958. PubMed PMID: 32023609; 11. Dukes JW, Dewland TA, Vittinghoff E, Mandyam MC, Heckbert SR, Siscovick DS, et al. Ventricular Ectopy as a Predictor of Heart Failure and Death. J Am Coll Cardiol. 2015;66(2):101–9. doi: 10.1016/j.jacc.2015.04.062. 12. Mariani JA et al. J Electrocardiol. 2020, 60; 13. Deneke et al  VOLUME 3, ISSUE 2, P152-159, APRIL 01, 2022, https://www.heartrhythmopen.com/article/S2666-5018(22)00044-7